NEW YORK (360Dx) – With a new €2.5 million ($3.1 million) grant, PixCell Medical Technologies aims to have its test on the European clinical market by early next year, followed by a launch in the US.

Yokneam, Israel-based PixCell was awarded the grant recently by the European Commission. With it, the firm plans support the development of its point-of-care testing device called HemoScreen, which it claims enables users to perform a complete blood count analysis within minutes.